skip to Main Content

November is Diabetes Awareness Month

The American Diabetes Association (ADA) has recognized November as Diabetes Awareness Month since 1975, and national Diabetes Day is November 14.

This marks an excellent time to bring awareness to the prevalence of diabetes among adults and adolescents in the United States.

It’s also an excellent time to encourage patients to seek testing for prediabetes. An estimated one in three adults in the U.S. has prediabetes, but most of them (a shocking 84 percent) are unaware of it.

This is why raising awareness about diabetes, including risk factors and preventative measures, is so important. When people understand that they can mitigate their risk of getting type 2 diabetes, they can potentially stave off the disease and instead live healthy lives.

Understanding Diabetes

There are two types of diabetes—type 1 and type 2. 

Type 1 diabetes happens because the body cannot make insulin. It is generally diagnosed during childhood, although it can develop in adulthood.

Type 2 diabetes is the more common form of the disease. It happens when the body doesn’t use insulin properly. Type 2 diabetes is often preventable and can be delayed or even reversed.

The Impact of Diabetes

When left untreated, both type 1 and type 2 diabetes can have severe effects, including stroke, heart disease, kidney damage, and nerve damage. 

Type 2 diabetes used to be considered something people got as they aged. However, we have recently seen an uptick in the number of people getting diagnosed earlier in life, including as kids or adolescents. 

The best way to prevent type 2 diabetes is to live a healthy lifestyle. This includes eating a diet full of whole foods and exercising regularly. In addition, smoking is another risk factor for type 2 diabetes, so quitting smoking or deciding never to start is another vital part of type 2 diabetes prevention. 

Diabetes Therapies on the Market

People with type 1 diabetes need to take insulin because their bodies don’t produce this hormone.

People with type 2 diabetes may need different therapies, depending on their specific situation. Some patients may use a combination of drug therapies, along with making lifestyle changes. 

Here are some of the most common types of diabetes therapies currently on the market. 

Alpha-glucosidase inhibitors

Drugs like Acarbose (Precose) and Miglitol (Glyset) lower blood sugar levels by blocking the breakdown of starches and sugars in the intestine. 

Biguanides

Drugs like Metformin (Glucophage) reduce how much glucose the liver produces and make it easier to absorb glucose. S

Bile acid sequestrants (BASs)

Drugs like colesevelam (Welchol) can be used to lower cholesterol and reduce blood sugar. These can be good for people who have liver problems that prevent them from using other medications.

Dopamine-2 Agonists

Bromocriptine (Cycloset and Parlodel) can lower blood sugar levels when taken after a meal. 

DPP-4 Inhibitors

This is a newer class of medications that can improve A1C blood counts without causing hypoglycemia. Some medications here include Alogliptin (Nesina), sitagliptin (Januvia), linagliptin (Tradjenta), and saxagliptin (Onglyza).

Meglitinides

Nateglinide (Starlix) and repaglinide (Prandin) are taken before meals to stimulate cells to release insulin. 

SGLT2 Inhibitors

This is another relatively new class of diabetes medications. Canagliflozin (Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance) help the kidneys reabsorb glucose resulting in excess glucose being secreted through urine. 

Sulfonylureas

These stimulate cells in the pancreas to release insulin. First-generation Chlorpropamide (Diabinese) is still used today, along with second-generation glimepiride (Amaryl), glipizide (Glucotrol and Glucotrol XL), and glyburide (Micronase, Glynase, and Diabeta). 

Thiazolidinediones (TZDs)

​​Rosiglitazone (Avandia) and pioglitazone (ACTOS) reduce glucose production in the liver.

Offer from HealthLink Dimensions

As a result of American Diabetes Month’s media campaigns and activities, many more men and women will make appointments with their nephrologist, ophthalmologist, podiatrist, or primary care provider. Therefore, Healthlink Dimensions has created a special program for lifescience, health insurer, and hospitals wishing to promote public service announcement (PSA) content to healthcare providers.

HealthLink Dimensions has created a custom programmatic segment targeting nephrologists, ophthalmologists, and podiatrists named “Diabetes Awareness” and available in LiveRamp. We have also reduced the cost for this programmatic segment price from $15.50 CPM to $5CPM through Nov 30, 2021, for PSA usage. All HealthLink Dimensions proceeds will be donated to the American Diabetes Association to fund diabetes research. Search for “HealthLink Dimensions Diabetes Awareness” in LiveRamp today and get started.

For those wishing to specifically identify physicians actively treating diabetes, HealthLink Dimensions’ Treatment Insights highlight the most valuable providers involved in the care and treatment of diabetic patients. An analysis of ICD-10 and Rx data reveals that HealthLink Dimensions has tens of thousands of verified email addresses for physicians who have treated diabetes in addition to many more nurse practitioners and physician assistants who are likely influential in the patient’s journey.

To learn more about Treatment Insights and how HealthLink Dimensions segments high-value healthcare providers within a particular diagnostic or therapeutic class, fill out the form or chat with us today.

Back To Top